Pitavastatin

Catalog No.E6038 Batch:E603801

Print

Technical Data

Formula

C25H24FNO4
Molecular Weight 421.46 CAS No. 147511-69-1
Solubility (25°C)* In vitro DMSO 84 mg/mL (199.3 mM)
Ethanol 42 mg/mL (99.65 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Homogeneous suspension for Oral and Intraperitoneal Injection. Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
4.200mg/ml Taking the 1 mL working solution as an example, add 50 μL of 84 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.350mg/ml Taking the 1 mL working solution as an example, add 50 μL of 7 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Pitavastatin (NK-104) is a highly potent inhibitor of HMG-CoA reductase with an IC50 of 6.8 nmol/L, which significantly enhances LDL receptor activity and lowers LDL cholesterol (LDL-C) levels. It also inhibits cholesterol synthesis in vitro and has the potential to manage hypercholesterolemia and reducing cardiovascular risk. 

Protocol (from reference)

Selleck's Pitavastatin has been cited by 3 publications

Enhancing Regulatory T cell function by mevalonate pathway inhibition prevents liver fibrosis [ Biochem Biophys Res Commun, 2025, 742:151094] PubMed: 39632293
YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis [ JCI Insight, 2024, 9(24)e178535] PubMed: 39704172
Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures [ Pharmaceuticals (Basel), 2024, 18(1)14] PubMed: 39861076

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.